Shafrin Defines Precision Medicine for U.S. News and World Report
In a new commentary for U.S. News and World Report, Jason Shafrin defines and elaborates on the field of precision medicine. Jason, IVI’s Director of Research, illustrates how the United States is moving headlong into this new treatment approach. He notes some of the challenges while also emphasizing the unique hope precision medicine brings through […]
IVI’s Mark Linthicum in Morning Consult: Why Understanding Value is Central to True Health Care Reform
Mark Linthicum makes the case that value-based spending should be the focus of health care reform efforts in Washington, D.C. On September 13th health care stakeholders came together at the National Press Club to discuss better approaches to measuring value. Read Full Article Here
Sachs Provides an Overview of FDA User Fee Reauthorization Bill
In a recent post on the IVI-Sponsored Health Affairs blog series, Rachel Sachs provides an overview of the House of Representative’s latest draft of the FDA user fee authorization bill. Sachs also examines changes in the bill from the earlier Senate markup, including incorporation of provisions from the bipartisan RACE Act and provides a possible […]
Discussing the Challenges of Value-Based Pricing in STAT News
In a new commentary for STAT News, Anupam Jena (part of IVI’s scientific advisory group) and Dana Goldman discuss the advantages of value-based pricing, pointing out several of the key challenges that complicate the application of health technology assessments. Jena and Goldman make the case that more transparency is needed and that an open-source model […]
IVI’s Lakdawalla in WSJ: Look to Major League Baseball for Drug Pricing Insight
In a new commentary appearing in The Wall Street Journal, Dana Goldman and IVI Executive Director, Darius Lakdawalla, turn to the national pastime to provide a fresh perspective on the issue of drug pricing and the return on investment pharmaceutical companies need to sustain innovation. In baseball, the salaries are high and the talent pool is […]
Discussing Value-Based Payments in Oncology
Dana Goldman, Darius Lakdawalla (Executive Director of IVI), and Lee Newcomer argue for an updated value-based payment system in oncology in the latest edition of the Health Affairs blog. Read the full article here.
Time to Dig Deeper When Evaluating Value In Healthcare
In Tomas Philipson’s latest Forbes.com op-ed, he and co-author Anupam Jena suggest it is time to stop scratching the surface when it comes to value in healthcare. Read the full article here.
Addressing Value Frameworks
Amitabh Chandra, Jason Shafrin (IVI Director of Research), and Ravider Dhawan examine the utility of cancer value frameworks in the latest edition of the Journal of the American Medical Association (JAMA). Read the full abstract here.
Discussing Access and Pricing for Generic Drugs
In a commentary for Modern Healthcare, Dana Goldman describes how access and pricing for generic drugs could be improved by taking a lesson from vaccine policy. Read the full article here.
Tackling the EpiPen Pricing Controversy
Dana Goldman addresses the firestorm created by Mylan’s dramatic price hikes for their EpiPen in a new commentary published in STAT News. Read the full article here.